2018 Update: Division of Rheumatology and Immunology

THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE • THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Looking back on 2017, I’m struck by a familiar feeling of fulfillment. As usual, my colleagues in the Division of Rheumatology and Immunology here at The Ohio State University have initiated or completed work that matters. Their contributions continue to make a difference within the field of rheumatology — and among the patients who turn to us for care.

As I reflect, I’ve been considering the idea of “connections.” The meaning of that word has shifted during the last 20 years. Today we often speak of connectivity in terms of new devices, apps and wireless technology. Because we are interconnected, we can reach a larger audience and get more done, more quickly than ever before.

I certainly rely on my smart phone and embrace the potential technology offers. But I’m also reminded that people are at the heart of all meaningful connections. It’s people who motivate us to find better treatments. And of course, people are responsible for all the scientific and medical accomplishments you’ll read about in these pages.

By partnering with colleagues across (and outside of) Ohio State, we’re strengthening patient care and bringing research from the bench to the bedside. For example:

• In July, Ohio State rheumatologist Alexa Meara, MD, helped launch a multidisciplinary vasculitis clinic along with pulmonologist Lynn Fussner, MD, nephrologist Salem Almaani, MBBS, and dermatologist Benjamin Kaffenberger, MD.

• We’re studying plasma thermograms, a promising new test for lupus, with Nichola Garbett, PhD, from the University of Louisville. Thanks to $1.8 million in NIH funding, by 2022 we may be closer to assessing lupus disease activity or organ involvement with a simple blood test. I’m proud to be part of this team along with my colleagues Stacy Ardoin, MD, Brad Rovin, MD, and Guy Brock, PhD.

• We launched a study with Dana Ascherman, MD, from the University of Miami to better understand inflammatory pathways in myositis. With the help of a $1.7 million NIH grant, we hope to identify new therapeutic targets for myositis and other inflammatory muscle diseases.

During the past year we also connected with our peers at professional conferences around the world:

• At the most recent American College of Rheumatology (ACR) meeting in San Diego, 23 of the accepted presentations were given by Ohio State faculty and fellows.

• Research presented at ACR by Nicholas Young, PhD, has also made international headlines, including publication in U.S. News & World Report. His ongoing studies in mouse models and humans suggest moderate exercise and stress reduction may suppress the inflammatory response in people with lupus.

I’d be remiss not to mention rheumatology’s rising stars. Our recently expanded fellowship program continues to attract some of the best and brightest minds. We recently completed interviews for our 2018-2019 program year. It was an impressive effort, considering we had 134 applicants — our strongest pool ever.

A final, shining example of human connection is my colleague Ronald Whisler, MD, former director of the Division I’m so fortunate to lead. A rheumatologist who has devoted his entire career to Ohio State, Dr. Whisler was recently recognized for his distinguished service with an endowed chair in his honor. When I think of the countless relationships he established with patients and their families during his 40-year career, I’m reminded of the profound difference one person can make.

Thank you for letting me share our 2017 achievements. I am inspired by the people who make Ohio State such a great place to work — and by the people we’re lucky enough to care for.

I encourage you to send me your comments or questions by e-mailing me at Wael.Jarjour@osumc.edu.

Welcome

Wael N. Jarjour, MD, FACP

Martha Morehouse Chair in Arthritis and Immunology ResearchDirector, Division of Rheumatology and ImmunologyThe Ohio State University College of MedicineThe Ohio State University Wexner Medical Center

Dear Friends and Colleagues,

Nicholas Young, PhD Ronald Whisler, MD

Ohio State Establishes $2 Million Endowed Chair in Rheumatology and ImmunologyRonald Whisler, MD, joined the faculty in The Ohio State University’s Division of Rheumatology and Immunology in 1977. Forty years later, in December 2017, Ohio State has created the Ronald L. Whisler, MD Chair in Rheumatology and Immunology.

The new position honors Dr. Whisler’s legacy and leadership, and will support a prominent physician or PhD faculty member specializing in immunology research. In addition to the initial endowment of $2 million, the Division of Rheumatology and Immunology will support the chair through ongoing fundraising efforts.

Dr. Whisler’s long history with Ohio State stretches back to 1968, when he graduated with his medical degree. After completing his residency in Internal Medicine at Ohio State in 1973, Dr. Whisler spent four years at the Mayo Clinic, where he obtained a clinical fellowship in Rheumatology and a research fellowship in Immunology.

The Ohio native returned to his roots in 1977, rejoining Ohio State as an assistant professor and quickly ascending to a leadership role. In 1980, Dr. Whisler became director of the Division of Rheumatology and Immunology — a position he held for 29 years.

“The division grew in size and scope under Dr. Whisler’s leadership,” says Wael Jarjour, MD, current director of Ohio State’s Division of Rheumatology and Immunology. “Not only did he usher in an era of modern rheumatology and immunology as director, he has also cared for countless people in central Ohio. Dr. Whisler is loved by his patients and respected by primary care physicians and rheumatologists across the region.”

Dr. Whisler, who is still an active member of the Division, says he felt surprised and honored when the new chair was announced.

“It’s a privilege to have the university recognize my career in this way,” he says. “But more importantly, the endowment lays the groundwork for continued expansion in the division. I’m happy to know we’ll be able to support a new investigator who is devoted to advancing our understanding of autoimmune diseases.”

Dr. Whisler was honored at a reception to mark the establishment of the endowed chair named for him. K. Craig Kent, MD, dean of The Ohio State University College of Medicine, gave the keynote address on Dr. Whisler’s remarkable career. Faculty, staff, and grateful patients in attendance also expressed their admiration and appreciation in celebration of his exceptional medical leadership and patient care.

On the Cover: Top: Sheryl Mascarenhas, MD, Bottom Left: Heather Hamilton, RN, Bottom Middle: Back Left to Right: Alexa Meara, MD, Kevin V. Hackshaw, MD, Stacy Ardoin, MD, Ali Ajam, MBBS, Ronald Whisler, MD and Sheryl Mascarenhas, MD, Front Left to Right: Wael Jarjour, MD, Beatrice Kenol, MD, Zhanna Mikulik, MD, Crystal Losambe, CNP and Hareth Madhoun, DO, Bottom Right: William Willis, PhD

The American College of Rheumatology (ACR) honored Joseph Flood, MD, FACP, a rheumatologist with the Columbus Arthritis Center and Clinical Professor of Internal Medicine at The Ohio State University College of Medicine, with the designation of Master during the 2017 ACR/ARHP Annual Meeting in San Diego. Recognition as a Master is one of the highest honors that the ACR bestows on its distinguished members.

“I am honored to be recognized for my commitment to advancing the health of patients with rheumatic diseases and teaching medical students and residents about these diseases. This is a capstone recognition culminating my service to the ACR as well.” said Dr. Flood. “I am truly humbled to receive this designation and join the ranks of many distinguished rheumatologists.”

Joseph Flood, MD receives Receives Top Honor from American College of Rheumatology

Ohio State’s Lupus Clinic

Back Left to Right: Hareth Madhoun, DO, Stacy Ardoin, MD, Lee A. Hebert, MD,Samir Parikh, MD and Salem Almaani, MBBS, Front Left to Right: Alexa Meara, MD, Wael Jarjour, MD, Brad Rovin, MD and Isabelle Ayoub, MD

Patient CareSeven Years After Launch, Ohio State’s Lupus Clinic Continues to FlourishThe Lupus Clinic at The Ohio State University continues to exceed expectations. In 2010, a group of four rheumatologists and nephrologists simply wanted to test whether lupus patients would benefit from seeing multiple specialists in a shared space. Today, their modest effort to streamline care is now a nationally renowned clinic with nine attending physicians, unique fellowship training opportunities and a robust research program.

Even though the clinic is widely regarded as a success, its providers are not willing to rest on their laurels. Team members continue to seek and implement new opportunities that make it easier for patients to manage their condition, and to live well despite their complex diseases.

Using research to foster understanding, bolster outcomes

The Lupus Clinic was also founded on a belief that eligible patients should have access to clinical trials. Seven years later, nearly half of the clinic’s patient population participates in studies for promising new therapies.

“The idea of using clinical research to improve patient care is exactly what we should be doing as an academic medical center,” says Brad Rovin, MD, director of the Division of Nephrology at The Ohio State University Wexner Medical Center.

“The Lupus Clinic’s model of care is similar to what we’ve seen in the field of oncology,” he explains. “Through a broad effort of aggressive clinical trial creation, management and recruitment, oncologists have been able to transform how cancer is treated, including reducing the side effects of chemotherapy and dramatically improving life expectancy. We’re hoping to have the same kind of transformative effect in patients with lupus.”

At any given time, the Lupus Clinic offers clinical trials for systemic lupus erythematosus as well as lupus nephritis, glomerular disease, vasculitis and other complex autoimmune diseases. Additionally, The Ohio State Lupus, Vasculitis and Glomerulonephritis Registry — now in its fourth year — collects clinical data and/or biospecimens so researchers can follow patients over time.

“To date we’ve added more than 420 patients to the registry,” says Stacy Ardoin, MD, chief of the Pediatric Rheumatology section at Nationwide Children’s Hospital, and the registry’s principal investigator. “It’s given us an unprecedented ability to better understand their condition, improve outcomes and conduct research on the pathogenesis and effects of lupus.”

Training the next generation of lupus experts

The Lupus Clinic’s scientific and clinical reputation has also attracted talented physicians seeking advanced training

in autoimmune disorders. Three to four senior fellows in rheumatology or nephrology rotate through the clinic each year. And physicians who want to sub-specialize in autoimmune diseases can apply for an additional year of fellowship that includes clinical and research training in lupus and glomerular diseases.

“Our fellowships provide tremendous opportunity and benefit to trainees and patients alike,” says Wael Jarjour, MD, director of Ohio State’s Division of Rheumatology and Immunology. “Graduates are leaving our program with specialized expertise and an interest in providing care that’s historically been hard to find. These physicians could one day start multidisciplinary clinics of their own, which strengthens care in the communities they serve.”

Patient education and support

Lupus is a life-altering disease that is still misunderstood. Even in communities where leading rheumatology or nephrology care is available, patients may feel like they’re facing uphill battles.

Knowing that supportive services can be just as vital as medical treatments, the Lupus Clinic offers patients a growing number of resources in conjunction with the Lupus Foundation of America. These include peer support groups, classes for newly diagnosed patients, and annual “lupus summits” where patients are invited to hear physicians discuss the latest advances in lupus care.

“Patients often say they appreciate the amount of time we spend answering questions,” says Dr. Rovin. “Many are young and just starting out, trying to come to terms with their diagnosis. They appreciate having someone to talk to about what to expect, including the side effects of treatment, whether they can work or finish school, and whether they can have children.”

Looking ahead

As the Lupus Clinic continues to evolve, it will do so with an eye toward helping patients who need highly specialized care. Additional programs under development include:

• A new multidisciplinary vasculitis clinic in collaboration with Ohio State pulmonologists, nephrologists and dermatologists

• A pediatric lupus clinic in collaboration with Nationwide Children’s Hospital

• Advanced care for pregnant women with autoimmune disease, in partnership with Ohio State’s Department of Obstetrics and Gynecology

To coordinate a physician-to-physician consultation or patient referral with Ohio State’s Lupus Clinic, please call 614-293-4837. Early intervention is ideal, as together we can manage your patient’s treatment plan — or enroll them in a clinical trial — before their disease is too advanced.

New Vasculitis Clinic Streamlines Patient Care, Stimulates Research

Building on the success of its multidisciplinary Lupus Clinic, The Ohio State University Wexner Medical Center has launched a new clinic that simplifies care for people with vasculitis.

The Vasculitis Clinic brings together experts in rheumatology, pulmonology, nephrology and dermatology, offering a convenient, one-stop experience for vasculitis patients who often require visits with multiple specialists. Working together in a shared space, providers can now quickly collaborate on the most challenging cases.

“We’re fortunate to have physicians at Ohio State who have experience diagnosing and managing all forms of vasculitis, including ANCA-associated disorders and large vessel subtypes,” says Alexa Meara, MD, an assistant professor in the Division of Rheumatology and Immunology who helped develop the Vasculitis Clinic. “We realized

we could make it even easier for people to obtain the care they need by collaborating under one roof. Now our vasculitis patients spend less time traveling to our individual offices, and they appreciate the collective knowledge we offer as a team.”

In addition to providing leading vasculitis care, the new clinic

also fosters investigator- and industry-sponsored research opportunities. Ohio State’s new vasculitis registry is already enrolling patients. Researchers will follow these patients over time to learn more about vasculitis to improve outcomes. In addition, a partnership with the international Vasculitis Clinical Research Consortium expands patient access to clinical trials.

Dr. Meara also conducts research on patient-physician communication, with the goal of improving patient health literacy and shared decision-making.

“I want to help make office visits more valuable, especially for patients who have complicated conditions,” explains Dr. Meara. “Our vasculitis patients often have multi-organ involvement and have fluctuating medication regimens. Improving their access to care is critical, but so too is making sure they understand their condition and how to manage it, such as taking their medications safely and knowing when to report side effects or new symptoms to their doctor.”

The Vasculitis Clinic was co-developed by Lynn Fussner, MD, assistant professor in Ohio State’s Division of Pulmonary, Critical Care, and Sleep Medicine. Team members also include nephrologist Salem Almaani, MD, MBBS, and dermatologist Benjamin Kaffenberger, MD.

To schedule a physician-to-physician consultation or coordinate a patient referral, please call 614-293-4837.

Alexa Meara, MD

Teamwork is Essential to Providing Excellent Patient Care

Some of our clinical team members are pictured here. Left to Right: Melissa Lashley, Tracy Walker, Myron Hobbs,Beth Liming, Tina Kirkling, Andi Gilliland, Shelley Brogan, and Kimberly Goodman

Clinic Staff patient models: Laurie Greenlaw (Cover), Nikki Bickers and Douglas Wagner (Research)

Research

A group of physicians and scientists from the University of Louisville School of Medicine and The Ohio State University Wexner Medical Center may be one step closer to diagnosing systemic lupus erythematosus using a simple blood test. Aided by a five-year, $1.8 million grant from the NIH, the six-person team will evaluate whether blood plasma “heat profiles” (plasma thermograms) can accurately detect lupus and indicate disease progression.

The study, led by Nichola Garbett, PhD, assistant professor at the University of Louisville, builds on her previous research showing plasma thermograms can reliably diagnose and stage cervical cancer. It will draw from Ohio State’s substantial pool of autoimmune-related biospecimens, including an active lupus registry that has enrolled more than 420 patients. And it will rely on the clinical experience of three physicians who help run Ohio State’s nationally renowned Lupus Clinic.

An emerging use of decades-old technology

Differential scanning calorimetry (DSC) is a thermal analysis technique often used to measure the heat capacity of natural and synthetic polymers and other materials. It’s used in a variety of industries, including pharmaceuticals and nanotechnology.

Dr. Garbett and her colleagues were among the first to apply DSC to biofluids, specifically human blood plasma. They found that when plasma is heated to a high temperature, its major proteins create a distinct shape or pattern. This unique profile, or thermogram, provides clues about a person’s health. Continued research has shown that plasma thermogram patterns correlate with specific diseases, ranging from cancer to type 1 diabetes, as well as different demographics.

“Thermograms could replace some of the more invasive procedures we use to test for specific organ involvement in lupus,” says co-investigator Wael Jarjour, MD, director of Ohio State’s Division of Rheumatology and Immunology. “An earlier study found key differences in plasma thermogram profiles of 300 lupus biospecimens compared to an equal number of matched controls. Speaking as a clinician and a scientist,

I’m excited to add to this body of work — and potentially remove much of the guesswork that comes with managing this disease.”

A laser focus on lupus

Along with Drs. Garbett and Jarjour, the research team includes Ohio State’s Stacy Ardoin, MD (rheumatologist), Guy Brock, PhD (bioinformatics) and Brad Rovin, MD (nephrologist), as well as Michael Merchant, PhD, a mass spectrometry and proteomics expert from the University of Louisville.

Together they’ll assess whether thermograms can improve early detection of lupus — a condition where the most relied upon laboratory tests have a high rate of false positives.

Their efforts will:

• Compare thermogram profiles to other diagnostic test results, including serological markers.

• Assess whether thermograms can distinguish between lupus and other autoimmune diseases, including rheumatoid arthritis.

• Determine whether thermograms are sensitive enough to detect lupus specific organ involvement or disease activity. For example, thermograms may be able to answer: Has organ damage already occurred? Is the patient in a period of remission or experiencing a flare-up?

• Confirm whether thermograms normalize when prescribed treatments are working.

• Use mass spectrometry to interrogate the plasma proteome, to better understand the biochemical basis of each thermogram profile and potentially identify novel biomarkers associated with lupus.

If validated, the team’s findings could provide the momentum needed to move plasma thermograms out of the research phase — and down the path toward licensing, FDA approval and widespread clinical adoption.

Beatrice Kenol, MD Crystal Losambe, CNPRheumatology’s clinical research team – Left to Right: Emily Sullivan, Kayla Knoll, and Kelly Morris

Researchers from University of Louisville and Ohio State Launch Landmark Study of New Diagnostic Test for LupusPlasma thermograms show promise in early detection, real-time monitoring of disease activity

Continuing Medical Education Conference: Clinical Applications of Musculoskeletal Ultrasound

Hareth Madhoun, DO, will lead a two-day, intensive workshop in Spring of 2019 featuring nationally and internationally known experts in the field of musculoskeletal ultrasound.

Registration will open in early 2019. For information or to register, please visit ccme.osu.edu. You can also visit our website at internalmedicine.osu.edu/rheumatology.

Rheumatology Fellowship Program

Back Left to Right: Kevin V. Hackshaw, MD, Paul Jensen, MD, Kai Quin, MD and Bryan Coniglio, MD Front Left to Right: Elaine Alexander, MD, Donald Whisler, MD, Veronica Mruk, MD and John Fleming, DO

Education

Renowned researchers from the University of Miami School of Medicine, the University of Pittsburgh, and The Ohio State University Wexner Medical Center have joined forces to investigate the mechanisms by which inflammation occurs in myositis.

Supported by a five-year, $1.7 million grant from the NIH, the team aims to better understand how the transcription factor NF-kB regulates innate immune response and impacts muscle inflammation and degeneration. They also hope to identify small molecule inhibitors that may prevent activation of key pathways associated with myositis and other inflammatory muscle diseases.

A novel model meets novel imaging

It’s broadly accepted that NF-kB helps turn on genes associated with the body’s immune response and inflammation. But the precise pathways that lead to muscle inflammation are not well understood.

To learn whether NF-kB activation triggers inflammatory cascades that lead to myositis, the team is using a unique, antigen-induced model created by principal investigator and rheumatologist Dana Ascherman, MD, from the University of Miami. It was the first model system generated by immunization with a protein called histidyl-tRNA synthetase (HRS). It recapitulates a subtype of myositis called antisynthetase syndrome — potentially making it more applicable to human disease.

“Previous iterations of our HRS-induced model not only produced muscle disease, but also lung disease, which is one of the most common extra-muscular targets of myositis,” says Dr. Ascherman. He explains that having a reliable working model is critical to understanding this condition. Because myositis is rare, it’s harder to conduct studies in humans.

“Our preliminary data suggests NF-kB is activated in the animal model, particularly in the initial phase of the autoimmune response,” says co-investigator Wael Jarjour, MD, director of Ohio State’s Division of Rheumatology and Immunology. “In this next phase of research, we want to define the direct and indirect pathways that lead to muscle inflammation.”

Dr. Jarjour and fellow Ohio State team members will help confirm the relationship between NF-kB activation and muscle dysfunction using in vivo assessment tools such as bioluminescent imaging. This imaging technique allows researchers to observe inflammation in live mice. When NF-kB is activated, areas of inflamed tissue glow.

From bench to bedside

While myositis can be treated with steroids and other medications, patients who take them are prone to severe side effects. If the team identifies relevant pathways that can be selectively targeted, it may lead to better treatments that do not pose the same risks as global immune-suppressing drugs.

“My team and I have collaborated with Dr. Ascherman on other projects going back several years,” says Dr. Jarjour. “Combining his expertise in cellular immunology and myositis, and our own experience with myositis animal models, is a natural next step that we hope will produce unprecedented results.”

University of Miami, University of Pittsburgh and Ohio State Launch Innovative Study of Inflammatory Pathways in MyositisCollaboration may lead to identification of novel therapeutic targets

Wael Jarjour, MD

The Ohio State University Wexner Medical Center

Rheumatology and Immunology

480 Medical Center Drive

Columbus, OH 43210

F I R S T C L A S S

U . S . P O S T A G E

P A I D

C o l u m b u s , O h i o

P e r m i t N o . 7 1 1

A selection of journal articles from the impressive list of publications authored or co-authored by our faculty:

Lake HM, Alexander EP, Mikulik Z, Hackshaw KV. Resistant Erythema Nodosum-Remembering an Old Treatment (Potassium Iodide). Gen Med (Los Angeles). 2017 Feb 28.5:286.

Yao Z, Mates JM, Cheplowitz AM, Hammer LP, Maiseyeu A, Phillips GS, Wewers MD, Rajaram MV, Robinson JM, Anderson CL, Ganesan LP. Blood-Bourne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-density Lipoprotein. Journal of Immunology. 2016 Sept 15;197(6):2390-9

Mina R, Harris JG, Klein-Gitelman MS, Appenzeller S, Centeville M, Eskra D,Huggins JL, Johnson AL, Khubchandani R, Khandekar P, Lee J, Liu HM, Pendl JD,Silva CA, Silva MF, Zaal AI, DeWitt EM, Ardoin SP, Brunner HI. Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016 Feb;68(2):179-86.

Mina R, Abulaban K, Klein-Gitelman MS, Eberhard BA, Ardoin SP, Singer N, Onel K, Tucker L, O’neil K, Wright T, Brooks E, Rouster-Stevens K, Jung L, Imundo L,Rovin B, Witte D, Ying J, Brunner HI. Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016 Feb;68(2):195-202

Ardoin SP and Jarjour WN. Biomarkers of Disease activity. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. George C. Tsokos, editor. Elsevier. Amsterdam. 43-49. Feb 2016

White PH, Ardoin S. Transitioning Wisely: Improving the Connection From Pediatric to Adult Health Care. Arthritis Rheumatol. 2016 Apr;68(4):789-94

Driest KD, Sturm MS, O’Brien SH, Spencer CH, Stanek JR, Ardoin SP; CARRA Registry Investigators. Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus. Lupus. 2016 Jun;25(7):749-53

Yen PY, Lara B, Lopetegui M, Bharat A, Ardoin S, Johnson B, Mathur P, Embi PJ, Curtis JR. Usability and Workflow Evaluation of “RhEumAtic Disease activitY” (READY). A Mobile Application for Rheumatology Patients and Providers. Appl Clin Inform. 2016 Nov 2;7(4):1007-1024.

Brunner HI, Bennett MR, Gulati G, Abulaban K, Klein-Gitelman MS, Ardoin SP, Tucker LB, Rouster-Stevens KA, Witte D, Ying J, Devarajan P. Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. JRheumatol. 2017 Aug;44(8):1239-1248.

Gulati G, Bennett MR, Abulaban K, Song H, Zhang X, Ma Q, Brodsky SV, Nadasdy T, Haffner C, Wiley K, Ardoin SP, Devarajan P, Ying J, Rovin BH, Brunner HI. Prospective validation of a novel renal activity index of lupus nephritis. Lupus. 2017 Aug;26(9):927-936.

Boneparth A, Radhakrishna SM, Greenbaum LA, Yen E, Okamura DM, Cooper JC, Mason S, Levy DM, Sule SD, Jensen PT, Yildirim-Toruner C, Ardoin SP, Wenderfer SE. Approach to Membranous Lupus Nephritis: A Survey of Pediatric Nephrologists and Pediatric Rheumatologists. J Rheumatol. 2017 Nov;44(11):1619-1623

Ganesan LP, Mates JM, Cheplowitz AM, Avila CL, Zimmerer JM, Yao Z, Maiseyeu A, Rajaram MV, Robinson JM, Anderson CL. Scavenger receptor B1, the HDL receptor, is expressed abundantly in liver sinusoidal endothelial cells. Scientific Reports. 2016 Feb 11;6:20646.

Mates JM, Yao Z, Cheplowitz AM, Suer O, Phillips GS, Kwiek JJ, Rajaram MV, Kim J, Robinson JM, Ganesan LP, Anderson CL. Mouse Liver Sinusoidal Endothelium Eliminates HIV-Like Particles from Blood at a Rate of 100 Million per Minute by a Second-Order Kinetic Process. Front Immunol. 2017 Jan 24;8:35. doi: 10.3389/fimmu.2017.00035. eCollection 2017.

Sharma J, Hampton J M, Valiente GR, Wada T, Steigelman H, Young MC, Spurbeck RR, Blazek A D, Bosh S, Jarjour WN, and Young NA.Therapeutic Development of Mesenchymal Stem Cells or Their Extracellular Vesicles to Inhibit Autoimmune-Mediated Inflammatory Processes in Systemic Lupus Erythematosus. Frontiers in Immunology.2017 May 10; 8:526

Aqel SI, Hampton JM, Bruss M, Jones KT, Valiente GR, Wu LC, Young MC, Willis WL, Ardoin S, Agarwal S, Bolon B, Powell N, Sheridan J, Schlesinger N, Jarjour WN, and Young NA. Daily Moderate Exercise Is Beneficial and Social Stress Is Detrimental to Disease Pathology in Murine Lupus Nephritis. Frontiers in Physiology. 2017 Apr 26; 8:236

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturm K, Ralpha D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Amifred W, Schlesinger LS, Azadf A, Rajaram MVS, Jarjour WN, Young NA, Rosol T, McGrath M. The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.  Nucl Med Biol. 2016 Mar;43(3):215-25

Garbett NC, Brock GN, Chaires JB, Mekmaysy CS, DeLeeuw L, Sivils KL, Harley JB, Rovin BH, Kulasekera KB, Jarjour WN. Characterization and classification of lupus patients based on plasma thermograms. PLoS One. 2017 Nov 17;12(11):e0186398. doi: 10.1371/journal.pone.0186398. eCollection 2017.PMID: 29149219

Meara A, Chan R, Husa M. A Case of TAILs,  Archives of Rheumatology, Volume 31 - Issue 4 - December 2016

Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Easley E, Gurcan M, Davis T, Gul A, Yazici Y, Zottenberg K, Esatoglu SN, Erer B, Kamali S, Yazici H, Cronholm PF, Merkel PA. Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. J Rheumatol. 2017 Nov;44(11):1750-1753. doi: 10.3899/jrheum.161352. Epub 2017 Apr 1.

Li D, Meara A, LaMoreaux B, Brock G, Jarjour WN Assessment of cardiovascular disease in rheumatoid arthritis patients. Arch Gen Intern Med. 2017;1(3):15-22

Toupin-April K, Barton J, Fraenkel L, Li LC, Brooks P, De Wit M, Stacey D, Légaré F, Meara A, Shea B, Lyddiatt A, Hofstetter C, Gossec L, Christensen R, Scholte-Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Pohl C, Jull JE, Sivarajah S, Campbell W, Alten R, Karuranga S, Morgan E, Kaufman J, Hill S, Maxwell LJ, Welch V, Beaton D, El-Miedany Y, Tugwell PS. Towards the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting., J Rheumatol. 2017 Oct;44(10):1544-1550. doi: 10.3899/jrheum.161241. Epub 2017 Aug 1.

Young NA, Valiente G, Hampton J, Wu LC, Burd C,Willis W, Bruss M, Steigelman H, Gotsatsenko M, Amici S, Severin M, Claverie L7, Guerau-de-Arellano M, Lovett-Racke A, Ardoin S, and Jarjour WN. Estrogen-regulated STAT1 activation promotes TLR8 overexpression to facilitate signaling via microRNA-21 in systemic lupus erythematosus. Clin Immunol. 2016 Dec 27

PHONE: 614-366-7016 • FAX: 614-366-0980 • INTERNALMEDICINE.OSU.EDU/RHEUMATOLOGY